Global Biologic Therapeutics Market 2015-2019 Key Vendors are Amgen, F. Hoffmann-La Roche, Novo Nordisk & Sanofi

DUBLIN, Nov. 09, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/l26l79/global_biologic) has announced the addition of the "Global Biologic Therapeutics Market 2015-2019" report to their offering.

The global biologic therapeutics market to grow at a CAGR of 8.26% over the period 2014-2019.

This report covers the present scenario and the growth prospects of the global biologic therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales protein therapeutics (monoclonal antibodies, enzymes, and other protein therapeutics).

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market. The report includes a discussion of the key vendors operating in this market.

Other protein therapeutics covers proteins such as cytokines, fusion proteins, peptide antibiotics, peptide hormones, and blood factors.

R&D in the market is rising in terms of the increasing collaborations between companies and the increase in mergers and acquisitions. For instance, in January 2014, Sanofi and Alnylam signed an agreement for the development of treatment therapies for rare genetic diseases.

According to the report, Biologic therapeutics are expensive and cannot be afforded by all, but the reimbursement of diagnostic kits and biologic drugs is expected to drive the market during the forecast period.

Further, the report states that competition is a major challenge for the market and varies depending on the disease. However, the market competition is negligible for biologics such as Fabrazyme, which is the only approved therapy in the US for the treatment of Fabry disease.

Key vendors

• Amgen
• F. Hoffmann-La Roche
• Novo Nordisk
• Sanofi

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: Market landscape

Part 06: Market segmentation by type of molecules

Part 07: Global protein therapeutics market

Part 08: Global vaccines market

Part 09: Global cell therapy market

Part 10: Geographical segmentation

Part 11: Market drivers

Part 12: Impact of drivers

Part 13: Market challenges

Part 14: Impact of drivers and challenges

Part 15: Market trends

Part 16: Vendor landscape

Part 17: Key vendor analysis

Part 18: Appendix

For more information visit http://www.researchandmarkets.com/research/l26l79/global_biologic

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com